866-997-4948(US-Canada Toll Free)

BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) - Pipeline Review, H2 2017

Published By :

Global Markets Direct

Published Date : Jul 2017

Category :

Pharmaceutical

No. of Pages : 108 Pages

BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) - Pipeline Review, H2 2017

Summary

BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) pipeline Target constitutes close to 19 molecules. Out of which approximately 15 molecules are developed by companies and remaining by the universities/institutes. The latest report BDNFNT 3 Growth Factors Receptor - Pipeline Review, H2 2017, outlays comprehensive information on the BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) - BDNF/NT-3 growth factors receptor is a protein encoded by the NTRK2 gene. It is involved in the development and the maturation of the central and the peripheral nervous systems through regulation of neuron survival, proliferation, migration, differentiation, and synapse formation and plasticity. It acts as receptor for BDNF/brain-derived neurotrophic factor and NTF4/neurotrophin-4. It alternatively can also bind NTF3/neurotrophin-3 which is less efficient in activating the receptor but regulates neuron survival through NTRK2. Upon ligand-binding, undergoes homodimerization, autophosphorylation and activation. The molecules developed by companies in Phase III, Phase I, Preclinical and Discovery stages are 3, 2, 6 and 4 respectively. Similarly, the universities portfolio in Preclinical stages comprises 4 molecules, respectively. Report covers products from therapy areas Central Nervous System, Oncology, Cardiovascular, Metabolic Disorders, Ear Nose Throat Disorders, Genetic Disorders and Ophthalmology which include indications Alzheimer's Disease, Breast Cancer, Solid Tumor, Bile Duct Cancer (Cholangiocarcinoma), Huntington Disease, Neuroendocrine Tumors, Non-Small Cell Lung Cancer, Pancreatic Cancer, Parkinson's Disease, Amyotrophic Lateral Sclerosis, Brain Cancer, Central Nervous System (CNS) Tumor, Colorectal Cancer, Melanoma, Metastatic Colorectal Cancer, Neuroblastoma, Ovarian Cancer, Papillary Thyroid Cancer, Post-Traumatic Stress Disorder (PTSD), Rett Syndrome, Salivary Gland Cancer, Soft Tissue Sarcoma, Stroke, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Adrenocortical Carcinoma (Adrenal Cortex Cancer), Anaplastic Large Cell Lymphoma (ALCL), Anxiety Disorders, Astrocytoma, Biliary Tumor, Bladder Cancer, Charcot-Marie-Tooth Disease, Colon Cancer, Depression, Diabetic Retinopathy, Endometrial Cancer, Epilepsy, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Fibrosarcoma, Gastrointestinal Stromal Tumor (GIST), Glioblastoma Multiforme (GBM), Head And Neck Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Hearing Disorders, Hepatocellular Carcinoma, Ischemic Optic Neuropathy, Kidney Cancer (Renal Cell Cancer), Lung Cancer, Major Depressive Disorder, Metastatic Adenocarcinoma of The Pancreas, Metastatic Brain Tumor, Metastatic Melanoma, Metastatic Renal Cell Carcinoma, Multiple Sclerosis, Neurology, Non-Rhabdomyosarcoma, Non-Small Cell Lung Carcinoma, Obesity, Ocular Melanoma, Pain, Peritoneal Cancer, Pheochromocytoma, Phobia, Pontine Glioma, Prostate Cancer, Refractory Acute Myeloid Leukemia, Refractory Multiple Myeloma, Relapsed Acute Myeloid Leukemia, Relapsed Multiple Myeloma, Renal Cell Carcinoma, Rhabdomyosarcoma, Sarcomas, Seizures, Skin Cancer, Tenosynovial Giant Cell Tumor, Thyroid Cancer, Transitional Cell Carcinoma (Urothelial Cell Carcinoma), Traumatic Brain Injury, Ureter Cancer, Urethral Cancer and Wilms' Tumor (Nephroblastoma).

Furthermore, this report also reviews key players involved in BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1)
- The report reviews BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) targeted therapeutics and enlists all their major and minor projects
- The report assesses BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) - Overview
BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) - Companies Involved in Therapeutics Development
Addex Therapeutics Ltd
Array BioPharma Inc
AstraZeneca Plc
Boehringer Ingelheim GmbH
Chronos Therapeutics Ltd
Daiichi Sankyo Company Ltd
Exelixis Inc
Ignyta Inc
Loxo Oncology Inc
Plexxikon Inc
Takeda Pharmaceutical Company Ltd
BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) - Drug Profiles
Antibodies to Agonize TrKB for Neurology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AR-523 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AZ-64 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AZD-7451 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BNN-27 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cabozantinib s-malate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CTDP-003 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DS-6051 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
entrectinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
larotrectinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LM-22A4 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LM-22B10 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PLX-7486 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
S-0131304 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Agonize TrkB Receptor for Central Nervous System, Metabolic Disorders and ENT Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize TrkA and TrkB for Alzheimers Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize TRKB for Neurodegenrative Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptide Agonize TrkA and TrkB Alzheimer's Disease and Amyotrophic Lateral Sclerosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptide to Agonize TrkB for CNS Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) - Dormant Products
BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) - Discontinued Products
BDNF/NT 3 Growth Factors Receptor (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) - Product Development Milestones
Featured News & Press Releases
Jun 19, 2017: Ipsen and its Partner Exelixis Announce Independent Radiology Committee Review Confirms Results from Phase 2 CABOSUN Trial of Cabozantinib versus Sunitinib in Previously Untreated Advanced Renal Cell Carcinoma
Jun 12, 2017: Exelixis Announces Initiation of Phase 1b Trial of Cabozantinib in Combination with Atezolizumab in Patients with Locally Advanced or Metastatic Solid Tumors
Jun 12, 2017: Scotland first in UK to make Cabometyx (cabozantinib) routinely available for individuals living with advanced kidney cancer
Jun 03, 2017: Loxo Oncology Breakthrough Therapy Larotrectinib Demonstrates 76 Percent Confirmed Objective Response Rate in TRK Fusion Adult and Pediatric Cancers as Presented at the American Society of Clinical Oncology Annual Meeting
Jun 03, 2017: New Drug Shows Durable Efficacy Across Diverse Pediatric and Adult Cancers
Jun 01, 2017: Ipsen To Present New Data of Cabometyx at ASCO
May 17, 2017: Loxo Oncology Announces Details of Two Larotrectinib Clinical Data Oral Presentations at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting
May 15, 2017: Ignyta Granted Breakthrough Therapy Designation for Entrectinib by U.S. Food and Drug Administration
May 12, 2017: Loxo Oncology Announces FDA Orphan Drug Designation Granted to Larotrectinib for the Treatment of Solid Tumors with NTRK-Fusion Proteins
Apr 27, 2017: Ignyta Updates Progress towards Entrectinib Dual TRK and ROS1 NDA Submissions
Apr 24, 2017: Ignyta to Host Conference Call and Webcast Update on Entrectinib Program and STARTRK-2 on April 27, 2017
Apr 05, 2017: Loxo Oncology Announces Acceptance of Larotrectinib Oral Presentations at the American Society of Clinical Oncology (ASCO) Annual Meeting
Apr 04, 2017: Ignyta Announces New Data on Entrectinib at the 2017 AACR Annual Meeting
Mar 31, 2017: Loxo Oncology Announces Proof of Concept Clinical Data for Larotrectinib in TRK Fusion Glioblastoma Presented at the AACR Annual Meeting 2017
Mar 30, 2017: Ignyta Announces Peer-Reviewed Publication of Activity of a TRK Inhibitor in a Primary Brain Tumor: Successful Treatment of Glioneuronal Tumor With Pan-TRK, CNS-Active Inhibitor Entrectinib Published in Precision Oncology
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development by Stage of Development, H2 2017
Number of Products under Development by Therapy Areas, H2 2017
Number of Products under Development by Indications, H2 2017
Number of Products under Development by Indications, H2 2017 (Contd..1), H2 2017
Number of Products under Development by Indications, H2 2017 (Contd..2), H2 2017
Number of Products under Development by Indications, H2 2017 (Contd..3), H2 2017
Number of Products under Development by Indications, H2 2017 (Contd..4), H2 2017
Number of Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Products under Development by Companies, H2 2017 (Contd..2), H2 2017
Products under Development by Companies, H2 2017 (Contd..3), H2 2017
Products under Development by Companies, H2 2017 (Contd..4), H2 2017
Products under Development by Companies, H2 2017 (Contd..5), H2 2017
Number of Products under Investigation by Universities/Institutes, H2 2017
Products under Investigation by Universities/Institutes, H2 2017
Number of Products by Stage and Mechanism of Actions, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Pipeline by Addex Therapeutics Ltd, H2 2017
Pipeline by Array BioPharma Inc, H2 2017
Pipeline by AstraZeneca Plc, H2 2017
Pipeline by Boehringer Ingelheim GmbH, H2 2017
Pipeline by Chronos Therapeutics Ltd, H2 2017
Pipeline by Daiichi Sankyo Company Ltd, H2 2017
Pipeline by Exelixis Inc, H2 2017
Pipeline by Ignyta Inc, H2 2017
Pipeline by Loxo Oncology Inc, H2 2017
Pipeline by Plexxikon Inc, H2 2017
Pipeline by Takeda Pharmaceutical Company Ltd, H2 2017
Dormant Projects, H2 2017
Discontinued Products, H2 2017

List of Figures
Number of Products under Development by Stage of Development, H2 2017
Number of Products under Development by Therapy Areas, H2 2017
Number of Products under Development by Top 10 Indications, H2 2017
Number of Products by Mechanism of Actions, H2 2017
Number of Products by Stage and Mechanism of Actions, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Molecule Types, H2 2017
Number of Products by Stage and Molecule Types, H2 2017

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *